Bryan Grissett, DO
Endocrinology, Diabetes & Metabolism · New Orleans, LANPI 1346747276
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,135 of the $8,276 with a category attached, or 86.2%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,225 and has fallen 62.9% since, to $1,565 in 2025.
Across 228 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$866
- Lilly USA, LLC$751
- Dexcom, Inc.$571
- Amgen$545
- Tandem Diabetes Care, Inc.$478
- plus $3K from 22 others
What the payments were for
- Travel & lodging$1,11713%
- Food & beverage$7,13586%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,797 |
| Novo Nordisk | 24 | $866 |
| Lilly USA, LLC | 41 | $751 |
| Dexcom, Inc. | 13 | $571 |
| Amgen | 22 | $545 |
| Tandem Diabetes Care, Inc. | 9 | $478 |
| BETA Bionics, Inc. | 9 | $374 |
| Bayer | 9 | $368 |
| Sanofi-aventis U.S. LLC | 14 | $328 |
| Novartis | 3 | $297 |
| Corcept Therapeutics | 12 | $275 |
| Esperion Therapeutics, Inc. | 4 | $264 |
| Boehringer Ingelheim | 16 | $235 |
| AbbVie | 9 | $199 |
| Sequel Med Tech, LLC | 3 | $158 |
| IBSA Pharma Inc. | 6 | $131 |
| Ascendis Pharma Endocrinology Inc | 1 | $120 |
| AstraZeneca | 1 | $109 |
| Insulet Corporation | 5 | $97 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Recordati_rare_diseases_inc. | 3 | $56 |
| Boston Scientific | 1 | $45 |
| Chiesi USA, Inc. | 2 | $45 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,392
- iLet Bionic Pancreas$450
- DEXCOM G6 TRANSMITTER$264
- t:slim X2 Insulin Pump with Control-IQ$239
- Ozempic$231
- NEXLIZET$228
- NEXLETOL$228
- Kerendia$227
- TWIIST$133
- RYBELSUS$125
- TEPEZZA$123
- EVENITY$122
- LEQVIO$111
- ENTRESTO$111
- FARXIGA$109
How this compares
$8,276 in reported general payments places this provider in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 321 | $408,271 |
| MounjaroTirzepatide | 301 | $344,293 |
| JardianceEmpagliflozin | 143 | $147,264 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $76,525 |
| FarxigaDapagliflozin Propanediol | 75 | $67,079 |
| TrulicityDulaglutide | 50 | $59,517 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $45,720 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 44 | $32,445 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $32,401 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $27,970 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $23,426 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $23,197 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 25 | $22,795 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $21,045 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $20,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $751 | $428,453409 claims |
| Novo NordiskOzempic | $866 | $408,271321 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $235 | $215,779211 claims |
| AstraZenecaFarxiga | $109 | $67,07975 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $328 | $23,42625 claims |
| IBSA Pharma Inc.Tirosint | $131 | $1,77513 claims |
| AbbVieSynthroid | $199 | $1,68316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in New Orleans
- Vivian FonsecaNew Orleans$658K
- Lawrence BlondeNew Orleans$142K
- Dragana LovreNew Orleans$14K
- Melina Roman-GerardinoNew Orleans$7K
- Mariam MenhemNew Orleans$5K
- Nyrene HaqueNew Orleans$5K
- Sarah SternliebNew Orleans$2K
- Suneeta GanjiNew Orleans$2K
- Timothy GilbertBaton Rouge$985K
- Abdul KhanHammond$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.